Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $2.4 million.

  • Journey Medical's Change in Receivables rose 17537.06% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 9823.09%. This contributed to the annual value of -$4.5 million for FY2024, which is 6434.55% up from last year.
  • According to the latest figures from Q3 2025, Journey Medical's Change in Receivables is $2.4 million, which was up 17537.06% from -$2.8 million recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's Change in Receivables peaked at $8.0 million during Q1 2022, and registered a low of -$10.4 million during Q2 2023.
  • Its 5-year average for Change in Receivables is -$254315.8, with a median of -$83000.0 in 2022.
  • Over the last 5 years, Journey Medical's Change in Receivables had its largest YoY gain of 1417058.82% in 2023, and its largest YoY loss of 1053855.42% in 2023.
  • Over the past 5 years, Journey Medical's Change in Receivables (Quarter) stood at -$8.5 million in 2021, then surged by 99.4% to -$51000.0 in 2022, then surged by 14170.59% to $7.2 million in 2023, then crashed by 110.41% to -$747000.0 in 2024, then skyrocketed by 423.29% to $2.4 million in 2025.
  • Its Change in Receivables stands at $2.4 million for Q3 2025, versus -$2.8 million for Q2 2025 and $8.0 million for Q1 2025.